Metsera gets $215m for obesity trials, and other financings
If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York startup Metsera.
Newsletters and Deep Dive digital magazine
If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York startup Metsera.
Welcome to, or welcome back to, the 5th Operationalize: Expanded Access Programs Summit 2025!
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density that could undermine its ability to compete in t
BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug.
A new report says that London is the top city in Europe for the life sciences industry, and ranks third worldwide after Boston and New York in the US.
Editor's Picks
Newsletters and Deep Dive
digital magazine